A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
NCT06179069
This study is recruiting at 10 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SCLC
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Last updated on ClinicalTrials.gov
- August 21, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Yale Cancer Center · New Haven, CT
Florida · 1
- Sarah Cannon Research Institute · Sarasota, FL
Michigan · 1
- Barbara Ann Karmanos Cancer Institute · Detroit, MI
New Jersey · 1
- Hackensack University Medical Center · Hackensack, NJ
New York · 1
- Roswell Park Comprehensive Cancer Center · Buffalo, NY
North Carolina · 1
- Duke University · Durham, NC
Ohio · 1
- University Hospitals Cleveland Medical Center · Cleveland, OH
Pennsylvania · 1
- University of Pittsburgh Hillman Cancer Center · Pittsburgh, PA
South Carolina · 1
- Medical University of South Carolina · Charleston, SC
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.